[ad_1] RT @RetinalPhys: This month we have a special edition of Retinal Physician, focused exclusively on #suprachoroidal therapy. It’s live now o… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] With potential approval of 1st “dry” #AMD treatments, we just published a timely review of molecular #genetics in 5 pathways implicated in AMD: #complement, extracellular matrix, #lipid, #angiogenesis & oxidative stress response. https://t.co/l1pScvIXNF #mdpigenes via @Genes_MDPI [ad_2] Source by Thomas Ciulla, MD, MBA Return …
[ad_1]
RT @ThomasCiullaMD: The @RetinalPhys special issue on #suprachoroidal #drugdelivery highlights its versatility with articles on biomechanic…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] OCT has revolutionized clinical #ophthalmology, given its rapid noninvasive assessment of the cross-sectional structure of the #retina. Here, we discuss #oct #biomarkers proposed as measures of disease severity and visual prognosis in uveitic macular edema… https://t.co/EaEPoH1Nxr [ad_2] Source by Thomas Ciulla, MD, MBA Return …
[ad_1] RT @ThomasCiullaMD: Congrats to colleagues & partners with numerous presentations involving #suprachoroidal delivery at last week’s @OISTW… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
The @RetinalPhys special issue on #suprachoroidal #drugdelivery highlights its versatility with articles on biomechanics, #clinicaltrials in FDA-approval of #Xipere for uveitic macular edema, & potential in ocular oncology therapy & #genetherapy delivery.
https://t.co/2YSkxZH5pi
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @ThomasCiullaMD: Just published: With the recent FDA-approval of #Xipere, clinicians are increasingly interested in Uveitic Macular Edem… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @ModernRetina: Survey respondents point to a perceived gap in treatments for uveitic macular edema, document interest in suprachoroidal… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @OphthTimes: Triamcinolone acetonide injectable suspension (Xipere, Bauch + Lomb) was launched recently as the first and only therapy ap…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] Just published: With the recent FDA-approval of #Xipere, clinicians are increasingly interested in Uveitic Macular Edema, the most common cause of vision loss in #uveitis. OCT Biomarkers in Uveitic Macular Edema on @RetinaToday https://t.co/T0JqXtkqf9 [ad_2] Source by Thomas Ciulla, MD, MBA Return to main …